Molecular Partners

decision path change of plans arrows business decision

Biotech

Molecular Partners tweaks AML trial over 'suboptimal exposure'

The biotech identified “suboptimal exposure” to its tetra-specific T-cell engager as the cause of the limited response rate in its early-phase trial.

Nick Paul Taylor Aug 27, 2024 10:00am

Resist resistance fight against cancer arrows out tumor immunotherapy

Amgen opts to DARP-out after seeing Molecular Partners data

Apr 26, 2022 4:38pm

Novartis splashes cash on COVID-19 antiviral, plans FDA filing

Jan 10, 2022 4:48am

Golden Gate Bridge in San Francisco

JPM22, Day 1: Bayer strikes a Mammoth deal and more

Jan 10, 2022 4:25am

Novartis tags Molecular Partners for $580M radioligand deal

Dec 14, 2021 10:34am

Concept of SARS-CoV-2 or COVID-19

Novartis-partnered DARPin flames out in COVID-19 study

Nov 16, 2021 8:15am